Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential

Overview

Journal Cell Mol Neurobiol

Publisher Springer

Specialties Cell Biology
Molecular Biology
Neurology

Date 2023 Apr 19

PMID 37074485

Authors

Dhritiman Roy

Shivaramakrishnan Balasubramanian

Praveen Thaggikuppe Krishnamurthy

Piyong Sola

Emdormi Rymbai

Affiliations

Soon will be listed here.

Abstract

Clinicians and researchers are exploring safer and novel treatment strategies for treating the ever-prevalent Parkinson's disease (PD) across the globe. Several therapeutic strategies are used clinically for PD, including dopamine replacement therapy, DA agonists, MAO-B blockers, COMT blockers, and anticholinergics. Surgical interventions such as pallidotomy, particularly deep brain stimulation (DBS), are also employed. However, they only provide temporal and symptomatic relief. Cyclic adenosine monophosphate (cAMP) is one of the secondary messengers involved in dopaminergic neurotransmission. Phosphodiesterase (PDE) regulates cAMP and cGMP intracellular levels. PDE enzymes are subdivided into families and subtypes which are expressed throughout the human body. PDE4 isoenzyme- PDE4B subtype is overexpressed in the substantia nigra of the brain. Various studies have implicated multiple cAMP-mediated signaling cascades in PD, and PDE4 is a common link that can emerge as a neuroprotective and/or disease-modifying target. Furthermore, a mechanistic understanding of the PDE4 subtypes has provided perceptivity into the molecular mechanisms underlying the adverse effects of phosphodiesterase-4 inhibitors (PDE4Is). The repositioning and development of efficacious PDE4Is for PD have gained much attention. This review critically assesses the existing literature on PDE4 and its expression. Specifically, this review provides insights into the interrelated neurological cAMP-mediated signaling cascades involving PDE4s and the potential role of PDE4Is in PD. In addition, we discuss existing challenges and possible strategies for overcoming them.

Citing Articles

Phosphodiesterase inhibition and Gucy2C activation enhance tyrosine hydroxylase Ser40 phosphorylation and improve 6-hydroxydopamine-induced motor deficits.

Douma E, Stoop J, Lingl M, Smidt M, van der Heide L Cell Biosci. 2024; 14(1):132.

PMID: 39456033 PMC: 11515495. DOI: 10.1186/s13578-024-01312-7.

Inhibition of Phosphodiesterase 4 Suppresses Neuronal Ferroptosis After Cerebral Ischemia/Reperfusion.

Chen K, Xu B, Long L, Wen H, Zhao Q, Tu X Mol Neurobiol. 2024; 62(3):3376-3395.

PMID: 39287745 DOI: 10.1007/s12035-024-04495-9.

cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment.

Zhang H, Liu Y, Liu J, Chen J, Wang J, Hua H J Hematol Oncol. 2024; 17(1):5.

PMID: 38233872 PMC: 10792844. DOI: 10.1186/s13045-024-01524-x.

PI3K/AKT signaling activation by roflumilast ameliorates rotenone-induced Parkinson's disease in rats.

Farid H, Sayed R, El-Shamarka M, Abdel-Salam O, Sayed N Inflammopharmacology. 2023; 32(2):1421-1437.

PMID: 37541971 PMC: 11006765. DOI: 10.1007/s10787-023-01305-x.

References

Kebabian J, Calne D . Multiple receptors for dopamine. Nature. 1979; 277(5692):93-6. DOI: 10.1038/277093a0. View

Gong J, Zhang L, Zhang Q, Li X, Xia X, Liu Y . Lentiviral Vector-Mediated SHC3 Silencing Exacerbates Oxidative Stress Injury in Nigral Dopamine Neurons by Regulating the PI3K-AKT-FoxO Signaling Pathway in Rats with Parkinson's Disease. Cell Physiol Biochem. 2018; 49(3):971-984. DOI: 10.1159/000493228. View

Choi J, Park C, Jeong J . AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun. 2009; 391(1):147-51. DOI: 10.1016/j.bbrc.2009.11.022. View

Tallei T, Fatimawali , Yelnetty A, Idroes R, Kusumawaty D, Emran T . An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. Front Pharmacol. 2021; 12:717757. PMC: 8417730. DOI: 10.3389/fphar.2021.717757. View

Oddo S . The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med. 2008; 12(2):363-73. PMC: 3822529. DOI: 10.1111/j.1582-4934.2008.00276.x. View

Demarch Z, Giampa C, Patassini S, Martorana A, Bernardi G, Fusco F . Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol Dis. 2006; 25(2):266-73. DOI: 10.1016/j.nbd.2006.09.006. View

Sun L, Stoecklin G, Van Way S, Hinkovska-Galcheva V, Guo R, Anderson P . Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J Biol Chem. 2006; 282(6):3766-77. DOI: 10.1074/jbc.M607347200. View

Wang G, Chen L, Pan X, Chen J, Wang L, Wang W . The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Oncotarget. 2016; 7(14):17380-92. PMC: 4951219. DOI: 10.18632/oncotarget.8041. View

Wang C, Ko H, Thomas B, Tsang F, Chew K, Tay S . Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet. 2005; 14(24):3885-97. DOI: 10.1093/hmg/ddi413. View

Robichaud A, Savoie C, Stamatiou P, Tattersall F, Chan C . PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology. 2000; 40(2):262-9. DOI: 10.1016/s0028-3908(00)00142-8. View

Bilge S, Gunaydin C, Onger M, Bozkurt A, Avci B . Neuroprotective action of agmatine in rotenone-induced model of Parkinson's disease: Role of BDNF/cREB and ERK pathway. Behav Brain Res. 2020; 392:112692. DOI: 10.1016/j.bbr.2020.112692. View

10.

Tang L, Huang C, Zhong J, He J, Guo J, Liu M . Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect. Eur J Med Chem. 2019; 168:221-231. DOI: 10.1016/j.ejmech.2019.02.026. View

11.

Vande Berg B, Beard W, Wilson S . DNA structure and aspartate 276 influence nucleotide binding to human DNA polymerase beta. Implication for the identity of the rate-limiting conformational change. J Biol Chem. 2000; 276(5):3408-16. DOI: 10.1074/jbc.M002884200. View

11.

Brown A, Deutch A, Colbran R . Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur J Neurosci. 2005; 22(1):247-56. PMC: 4819997. DOI: 10.1111/j.1460-9568.2005.04190.x. View

12.

Wachtel H . Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berl). 1982; 77(4):309-16. DOI: 10.1007/BF00432761. View

12.

Jones D, Head I, Gray N, Adams J, Rowan A, Aitken C . Crude-oil biodegradation via methanogenesis in subsurface petroleum reservoirs. Nature. 2007; 451(7175):176-80. DOI: 10.1038/nature06484. View

13.

Tashkin D . Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2013; 15(1):85-96. DOI: 10.1517/14656566.2013.837159. View

14.

Bhat N, Zhang P, Bhat A . Cytokine induction of inducible nitric oxide synthase in an oligodendrocyte cell line: role of p38 mitogen-activated protein kinase activation. J Neurochem. 1999; 72(2):472-8. DOI: 10.1046/j.1471-4159.1999.0720472.x. View

14.

Zhong J, Xie J, Xiao J, Li D, Xu B, Wang X . Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP-induced oxidative insult. Free Radic Biol Med. 2019; 135:87-101. DOI: 10.1016/j.freeradbiomed.2019.02.027. View

15.

McDonough W, Rich J, Aragon I, Abou Saleh L, Boyd A, Richter A . Inhibition of type 4 cAMP-phosphodiesterases (PDE4s) in mice induces hypothermia via effects on behavioral and central autonomous thermoregulation. Biochem Pharmacol. 2020; 180:114158. PMC: 7606724. DOI: 10.1016/j.bcp.2020.114158. View